MMV welcomes projects in the hit-to-lead and lead optimization stages for new families of molecules specifically addressing the key priorities of the malaria eradication agenda: transmission blocking via the human host, and prevention of P. vivax relapse through killing of liver stage hypnozoites or reactivating them so as to be killed in the blood stages.
In addition, proposals are sought for novel chemical series with a long half-life (ideally >10h in rodents) and confirmed in vivo efficacy that could have potential for well tolerated P. falciparum chemoprophylaxis or asexual blood stage treatment in humans. Any proposals based on existing chemotypes must clearly address known issues.
Please note that early target validation falls outside of our mandate.
Finally, we also welcome proposals on novel translational study concepts that enable early confirmation of relapse prevention, transmission blocking and prophylactic activity in humans.
Further instructions and the application template can be found on the right-hand side of this page. All applications using the specified template should be sent electronically to proposals [at] mmv.org by 12 noon CET March 15th, 2013.